Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...8081828384858687888990...123124»
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  CT imaging findings of lenvatinib-induced enteritis. (Pubmed Central) -  Jun 26, 2021   
    Sponsored By Eisai-MSD Lenvatinib-induced enteritis frequently involved the duodenum and jejunum and was related to a significantly higher frequency of treatment interruptions and gastrointestinal adverse events.
  • ||||||||||  lenvatinib / Generic mfg.
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Lenvatinib in Management of Solid Tumors. (Pubmed Central) -  Jun 22, 2021   
    In addition, they will learn that different strengths of lenvatinib are prescribed and why. Finally, readers are pointed to the latest efforts to combine lenvatinib and pembrolizumab, as well as to unresolved issues such as long-term side effects/toxicities of this drug.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Journal, HEOR:  Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. (Pubmed Central) -  Jun 22, 2021   
    This cost-utility analysis showed that lenvatinib had a similar clinical effectiveness at a lower cost than sorafenib, indicating that lenvatinib may be a cost-saving measure in patients with unresectable HCC, in which $23,719 could be saved per patient. The introduction of a new therapeutic option for the first time in 10 years in Canada provides an important opportunity for clinicians, researchers, and health care decision-makers to explore potential modifications in recommendations and practice guidelines.
  • ||||||||||  lenvatinib / Generic mfg.
    Clinical, Journal:  Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina. (Pubmed Central) -  Jun 22, 2021   
    Tumor responses and PFS in our study were in line with other real-life clinical data and they seem to be inferior to the reported in the SELECT trial, probably related to the higher number of patients with prior MKI therapy, comorbidities, and poor performance status. Although virtually all patients experienced AEs, most of them were manageable and rarely a definitive withdrawal was necessary.
  • ||||||||||  Clinical, Review, Journal, PD(L)-1 Biomarker:  Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. (Pubmed Central) -  Jun 22, 2021   
    Over time, first-line treatment frequently fails, and regorafenib, cabozantinib, ramucirumab (for patients with alpha fetoprotein ≥400 ng/mL), nivolumab, pembrolizumab and ipilimumab plus nivolumab are approved for use after sorafenib (but not lenvatinib) treatment in advanced HCC...The approval of new combination therapies for advanced HCC in the first-line setting will further increase the complexity of decision-making. However, the important factors will remain the individual patient's characteristics and preferences.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Quantification of sorafenib, lenvatinib, and apatinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS. (Pubmed Central) -  Jun 22, 2021   
    This method presented satisfactory results in terms of specificity, precision (coefficient of variation of intra-day and inter-day:1.4-6.6 %), accuracy (92.6-105.4 %), matrix effects (96.9-107.2 %), extraction recovery (90.5-99.4 %), as well as stability in human plasma and even whole blood under certain conditions. This sensitive, rapid and simple method was successfully applied to the analysis of sorafenib, lenvatinib and apatinib for therapeutic drug monitoring in hepatocellular carcinoma patients, and it was expected to be applied to further study about clarifying the concentration- efficacy and concentration-toxic relationship of sorafenib, lenvatinib, and apatinib in hepatocellular carcinoma patients.
  • ||||||||||  lenvatinib / Generic mfg.
    Preclinical, Journal:  Lenvatinib Induces AKT/NF-κB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer In Vivo. (Pubmed Central) -  Jun 22, 2021   
    This sensitive, rapid and simple method was successfully applied to the analysis of sorafenib, lenvatinib and apatinib for therapeutic drug monitoring in hepatocellular carcinoma patients, and it was expected to be applied to further study about clarifying the concentration- efficacy and concentration-toxic relationship of sorafenib, lenvatinib, and apatinib in hepatocellular carcinoma patients. Induction of apoptosis and suppression of AKT/NF-κB were associated with lenvatinib-induced inhibition of the progression of NSCLC in vivo.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Review, Journal:  Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer. (Pubmed Central) -  Jun 16, 2021   
    We found that phosphoglycerate dehydrogenase, a critical enzyme for serine biosynthesis, could be a novel therapeutic target, and that the lymphocyte-to-monocyte ratio is a prognostic marker of survival in patients with anaplastic thyroid carcinoma or RAIR DTC. Deeper insights are needed into tumor-host interactions in thyroid cancer to improve treatment.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Effect of miR-23b on the malignant phenotype and the sensitivity of lenvatinib in human hepatocellular carcinoma cells (Pubmed Central) -  Jun 16, 2021   
    In addition, EdU results showed that after miR-23b combined with lenvatinib, the positive rates of EdU staining of hepatocellular carcinoma cell line HepG2 and SMMC-7721 in the miR-23b mimic group were (32.905 ± 1.342)% and (24.811 ± 0.820)%, respectively, which were significantly lower than the control group (52.623 ± 2.441)% and (38.702 ± 1.312)% (P < 0.05). miR-23b can inhibit the proliferation, migration, invasion and vasculogenic mimicry formation, and enhance the sensitivity of lenvatinib drug in human hepatocellular carcinoma cells.